Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tenapanor (RDX 5791) is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,500 | |||
5 mg | 在庫あり | ¥ 16,500 | |||
10 mg | 在庫あり | ¥ 27,000 | |||
25 mg | 在庫あり | ¥ 57,000 | |||
50 mg | 在庫あり | ¥ 89,500 | |||
100 mg | 在庫あり | ¥ 133,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 72,000 |
説明 | Tenapanor (RDX 5791) is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects. |
ターゲット&IC50 | NHE3 (human):5 nM (IC50), NHE3 (rat):10 nM (IC50) |
別名 | RDX-5791, RDX 5791, AZD 1722, Tenapanor free base, RDX5791, AZD-1722, AZD1722 |
分子量 | 1145.05 |
分子式 | C50H66Cl4N8O10S2 |
CAS No. | 1234423-95-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (43.67 mM), Sonication is recommended.
H2O: < 0.1 mg/mL (insoluble)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tenapanor 1234423-95-0 Membrane transporter/Ion channel Sodium Channel RDX-5791 inhibit Sodium-hydrogen Exchanger intestinal RDX 5791 AZD 1722 Tenapanor free base hyperphosphatemia Sodium/hydrogen Exchanger RDX5791 AZD-1722 AZD1722 Inhibitor orally active Na+/H+ Exchanger (NHE) phosphate absorption inhibitor